BioMarin Pharmaceutical Inc.
BMRN | NASDAQ
$63.87
-$0.19 (-0.30%)
Sep 22, 2026, 2:34 PM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | 3.22B | 2.85B | 2.42B | 2.1B | 1.85B | 1.86B |
Cost of Revenue | 736.83M | 580.24M | 532.06M | 503.02M | 470.52M | 524.27M |
Gross Profit | 2.48B | 2.27B | 1.89B | 1.59B | 1.38B | 1.34B |
Operating Income | 533.48M | 484.21M | 185.77M | 160.97M | -82.34M | -43.44M |
Interest Income | 74.9M | 74.88M | 58.34M | 18.03M | 10.48M | 16.61M |
Pretax Income | 482.48M | 541.76M | 188.56M | 149.58M | -75.35M | -49M |
Net Income | 348.9M | 426.86M | 167.65M | 141.56M | -64.08M | 854.03M |
Selling & General & Admin | 1.28B | 1.01B | 892.4M | 823.2M | 759.4M | 737.7M |
Research & Development | 921.93M | 747.18M | 746.77M | 649.61M | 628.79M | 628.12M |
Other Expenses | -248M | 33.28M | 62.22M | -40.76M | 69.91M | 13.81M |
Operating Expenses | 1.95B | 1.79B | 1.7B | 1.43B | 1.46B | 1.38B |
Interest Expense | 10.9M | 12.67M | 17.34M | 15.97M | 15.34M | 29.31M |
Selling & Marketing Expenses | 124M | 476.7M | 488.4M | 450.3M | 405.1M | 403.4M |
Cost & Expenses | 2.69B | 2.37B | 2.23B | 1.94B | 1.93B | 1.9B |
Income Tax Expense | 133.58M | 114.9M | 20.92M | 8.02M | -11.27M | -903.03M |
Shares Outstanding (Basic) | 191.79M | 190.03M | 187.83M | 185.27M | 182.85M | 180.8M |
Shares Outstanding (Diluted) | 197.39M | 196.71M | 191.6M | 188.96M | 182.85M | 191.68M |
EPS (Basic) | 1.82 | 2.25 | 0.89 | 0.76 | -0.35 | 4.75 |
EPS (Diluted) | 1.80 | 2.21 | 0.88 | 0.75 | -0.35 | 4.53 |
EBITDA | 572.94M | 650.53M | 306.77M | 265.36M | 47.43M | 83.66M |
EBIT | 493.38M | 554.1M | 202.39M | 163.39M | -60.61M | -21.52M |
Depreciation & Amortization | 79.56M | 96.43M | 104.39M | 101.97M | 108.04M | 105.17M |
Add to Watchlist
Select watchlists to add or remove BMRN